Skip to main content

Table 3 Pearson correlations between changes from baseline to week 24 in each estimated fluid volume and clinical variables of interest

From: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

Variables ePV eEV
Coefficient P value Coefficient P value
Systolic blood pressure 0.090 0.542 0.374 0.007
Diastolic blood pressure 0.095 0.520 0.186 0.195
Body mass index − 0.143 0.333 0.986  < 0.001
Uric acid − 0.091 0.546 0.132 0.380
Fasting plasma glucose 0.138 0.361 − 0.081 0.591
Glycohemoglobin − 0.287 0.048 − 0.027 0.855
eGFRa 0.407 0.005 − 0.091 0.538
UACRa − 0.011 0.949 0.038 0.817
High-sensitivity troponin Ia 0.177 0.240 0.252 0.091
Total ketone bodiesa 0.029 0.855 − 0.013 0.937
RHIa − 0.184 0.215 0.155 0.298
  1. RHI reactive hyperemia index. Others see Table 1
  2. aLog-transformed